DataMEDS AI, Inc.(MEDS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.74
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for MEDS

11/13/2026: MEDS (1-star) is currently NOT-A-BUY. Pass it for now.

DataMEDS AI, Inc. is a micro-capitalization healthcare technology and pharmaceutical distribution company focused on independent pharmacies. Its primary strengths lie in its integrated platform combining wholesale logistics with proprietary AI tools like EinsteinRx. The main investment growth story centers on scaling its digital health software adoption across a national pharmacy network. However, the company faces substantial risks, including high stock price volatility, intense competition from legacy distributors, and unproven profitability. This stock is best suited for speculative growth investors willing to monitor ongoing cash burn and technology execution milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile operating in high-growth health tech verticals, the early-stage nature creates execution uncertainty.
Momentum investorStrong fit while signal remains positiveMicro-cap status can trigger sharp price movements when positive technological or partnership catalysts occur.
Value investorWeak fitThe lack of consistent earnings and profitability metrics makes traditional value investing models inapplicable.
Dividend investorWeak fitThe company pays no dividends and retains all capital for business expansion.
Low-risk investorWeak fitHigh share price volatility and micro-cap liquidity risks expose investors to substantial capital loss.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighLow trading floats and micro-cap status lead to extreme daily price swings.
Valuation riskMedium / highPricing is heavily sentiment-driven rather than anchored by stable earnings multiples.
Competition risk (AI and distribution competition)HighThe company competes against massive, well-capitalized wholesale and technology incumbents.
Business qualityMediumThe integrated business model shows promise but is still unproven at a large scale.
Dividend incomeLow / noneNo dividend yield is offered to shareholders.
Execution riskHighManagement must successfully execute complex technological integrations and scale distribution channels simultaneously.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.86M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 1.9M shares
Beta -
52 Weeks Range 0.55 - 35.50
Updated Date 11/15/2026
52 Weeks Range 0.55 - 35.50
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -46.68

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Distribution

BUY participation
100.0%
Active BUY / eligible
3 / 3
30-Day BUY Count Change
+2

Eligible universe: 3 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -20.65%
Avg. Invested days 2
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
MEDS receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft company fundamentals, and soft analyst coverage.

Company Fundamentals

★★★★★
MEDS has soft overall fundamentals (2 stars), with weak financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, solid revenue growth (+28.7%) is partially offset by negative earnings growth (-1377.1%), weak cash generation (FCF margin -50.3%), weak profitability (net margin -433.9%).

Financial Health Rating

★★★★★
MEDS's financial health is weak, with the relatively strongest area being soft liquidity, including working-capital and asset support (WC/assets -88.5%). Operating efficiency is weak (1 stars), which helps explain the 1-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is MEDS's strongest growth driver at +28.7% FY2025 versus FY2024 (solid, 4 stars). By comparison, while earnings growth (-1377.1%, negative) and free-cash-flow growth (-632.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 1.8% (soft) and 28.1% of outstanding shares are publicly tradable (soft). Insider ownership of 44.20% supports management-shareholder alignment.

Top 5 Institutional Investors

Jane Street Group LLC 0.72%
Geode Capital Management, LLC 0.44%
Vanguard Capital Management, LLC 0.39%
Vanguard Fiduciary Trust Co 0.22%
Barclays PLC 0.03%

Unit Economics (Per $1K Revenue)

★★★★★
MEDS generates approximately $-413 of gross profit, $-3,479 of operating income, and $-503 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
MEDS has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Pharmaceutical DistributionWholesale distribution of pharmaceuticals and health products to independent pharmacy networks.Generates traditional wholesale supply chain revenue through product delivery.
Health IT and Software ServicesSubscriptions or platform fees derived from AI tools like EinsteinRx and PharmacyChain.Provides higher-margin technology services designed to modernize pharmacy workflows.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 33.69M
Price to Sales(TTM) 0.48
Enterprise Value 33.69M
Price to Sales(TTM) 0.48
Enterprise Value to Revenue 4.2
Enterprise Value to EBITDA -
Shares Outstanding 5.18M
Shares Floating 1.46M
Shares Outstanding 5.18M
Shares Floating 1.46M
Percent Insiders 44.2
Percent Institutions 1.77

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.